Literature DB >> 21568930

Bitter gourd (Momordica charantia) is a cornucopia of health: a review of its credited antidiabetic, anti-HIV, and antitumor properties.

E F Fang1, T B Ng.   

Abstract

Bitter gourd (Momordica charantia, BG) is both a nutritious and healthy food with a distinctive bitter flavor, and it is also widely exploited in folklore medicine. This review focuses on the efficacies and molecular mechanisms of BG-induced anti-diabetic, anti-HIV, and antitumor activities contributed by over twenty active components. The intent of this review is to provide comprehensive and valuable information for medicinal researchers, drug investigators, clinicians, and even patients with an interest in BG. In conclusion, BG is a cornucopia of health and it deserves in-depth investigations for clinical application in the future.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21568930     DOI: 10.2174/156652411795976583

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  21 in total

1.  Cucurbitane-Type Triterpenoids from the Vines of Momordica charantia and Their Anti-inflammatory Activities.

Authors:  Hung-Tse Huang; Li-Jie Zhang; Hui-Chi Huang; Syh-Yuan Hwang; Chia-Lun Wu; Yu-Chi Lin; Chia-Ching Liaw; Yung-Yi Cheng; Susan L Morris-Natschke; Chung-Yi Huang; Kuo-Hsiung Lee; Yao-Haur Kuo
Journal:  J Nat Prod       Date:  2020-05-01       Impact factor: 4.050

Review 2.  Bitter melon: a panacea for inflammation and cancer.

Authors:  Prasad R Dandawate; Dharmalingam Subramaniam; Subhash B Padhye; Shrikant Anant
Journal:  Chin J Nat Med       Date:  2016-02

3.  MAP30 promotes apoptosis of U251 and U87 cells by suppressing the LGR5 and Wnt/β-catenin signaling pathway, and enhancing Smac expression.

Authors:  Yilin Jiang; Junjie Miao; Dongliang Wang; Jingru Zhou; Bo Liu; Feng Jiao; Jiangfeng Liang; Yangshuo Wang; Cungang Fan; Qingjun Zhang
Journal:  Oncol Lett       Date:  2018-02-16       Impact factor: 2.967

Review 4.  Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.

Authors:  Komal Raina; Dileep Kumar; Rajesh Agarwal
Journal:  Semin Cancer Biol       Date:  2016-07-21       Impact factor: 15.707

5.  Antileukemic Potential of Momordica charantia Seed Extracts on Human Myeloid Leukemic HL60 Cells.

Authors:  Ramani Soundararajan; Punit Prabha; Umesh Rai; Aparna Dixit
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-13       Impact factor: 2.629

6.  Antibacterial and Antiproliferative Activities of Plumericin, an Iridoid Isolated from Momordica charantia Vine.

Authors:  Jutamas Saengsai; Sumonthip Kongtunjanphuk; Nuttawan Yoswatthana; Tanawan Kummalue; Weena Jiratchariyakul
Journal:  Evid Based Complement Alternat Med       Date:  2015-04-07       Impact factor: 2.629

7.  De Novo Assembly of Bitter Gourd Transcriptomes: Gene Expression and Sequence Variations in Gynoecious and Monoecious Lines.

Authors:  Anjali Shukla; V K Singh; D R Bharadwaj; Rajesh Kumar; Ashutosh Rai; A K Rai; Raja Mugasimangalam; Sriram Parameswaran; Major Singh; P S Naik
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

8.  Momordica charantia Extract Induces Apoptosis in Human Cancer Cells through Caspase- and Mitochondria-Dependent Pathways.

Authors:  Chia-Jung Li; Shih-Fang Tsang; Chun-Hao Tsai; Hsin-Yi Tsai; Jong-Ho Chyuan; Hsue-Yin Hsu
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-04       Impact factor: 2.629

9.  Effect of superfine grinding on antidiabetic activity of bitter melon powder.

Authors:  Ying Zhu; Ying Dong; Xiwen Qian; Fengjie Cui; Qin Guo; Xinghua Zhou; Yun Wang; Yi Zhang; Zhiyu Xiong
Journal:  Int J Mol Sci       Date:  2012-11-02       Impact factor: 5.923

10.  Trichosanthin inhibits breast cancer cell proliferation in both cell lines and nude mice by promotion of apoptosis.

Authors:  Evandro Fei Fang; Chris Zhi Yi Zhang; Lin Zhang; Jack Ho Wong; Yau Sang Chan; Wen Liang Pan; Xiu Li Dan; Cui Ming Yin; Chi Hin Cho; Tzi Bun Ng
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.